A study evaluating lipoprotein profile resulting from NGM282and effect of rosuvastatin on these changes in biopsy confirmed non alcoholic steatohepatitis patients.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2018
At a glance
- Drugs NGM 282 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacodynamics
- 06 Nov 2018 According to a NGM Biopharmaceuticals media release, data from the 3 mg biopsy cohort were presented at The International Liver Congress in Paris in April 2018.
- 06 Nov 2018 According to a NGM Biopharmaceuticals media release, new data from the 1 mg biopsy cohort from this trial will be presented at The Liver Meeting of The American Association for the Study of Liver Diseases.
- 16 Nov 2017 New trial record